Reni Benjamin

H.C. Wainwright Reiterates Buy On OncoSec Following FY4Q14 Results

In a research report published today, H.C.

Editor Ben Weinberg — October 16, 2014, 11:54 AM EDT

H.C. Wainwright Reiterates Buy On Capricor As It Plans To Pursue A Cenderitide Clinical Program

In a research note issued to investors today, analyst Reni Benjamin of H.C.

Ben Mahaney, Editor — October 13, 2014, 3:53 PM EDT

Neuralstem Shares Are Currently Fairly Valued, Says H.C. Wainwright

In a research report sent to investors today, H.C.

Ben Mahaney, Editor — October 13, 2014, 3:25 PM EDT

Capricor Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research report issued today, H.C.

Corey Williams — October 7, 2014, 4:54 PM EDT

H.C. Wainwright Reiterates Buy On Fate Therapeutics Following Meeting With Management

In a research report issued today, H.C.

Scott Fields Scott Fields — October 7, 2014, 4:08 PM EDT

H.C. Wainwright Reiterates Buy On Cesca Therapeutics Following Release Of Its Service-Related Revenues

In a research note released today, H.C.

Editor Ben Weinberg — September 30, 2014, 5:06 PM EDT

H.C. Wainwright Reiterates Buy On Keryx Following Initiation Of A New Phase 3 Study

In a research report released today to investors, H.C.

Ben Mahaney, Editor — September 30, 2014, 2:32 PM EDT

H.C. Wainwright Reiterates Buy On Ariad Following Clinical Data On AP26113

In a research report released today, H.C.

Ben Mahaney, Editor — September 30, 2014, 1:10 PM EDT

H.C. Wainwright Comments On Neuralstem Following Presentation At The Annual Symposium On ALS

In a research report issued today, H.C.

Scott Fields Scott Fields — September 23, 2014, 3:40 PM EDT

H.C. Wainwright Reiterates Buy On Oxigene Following Initiation Of Phase 2 Study

In a research report issued today, H.C.

Ben Mahaney, Editor — September 22, 2014, 2:50 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts